Background. To obtain reliable clinical data of human immunodeficiency virus type 1 group O (HIV-1/O) infection, and immunovirological responses to combination antiretroviral therapy (cART), in a large series of 101 patients.
responses to antiretroviral therapy (ART) is not well known [24] [25] [26] [27] [28] [29] [30] . This lack of data on bioclinical outcomes has led to empiric therapeutic management, similar to that of HIV-1/M infection, without knowing if it is well adapted.
The aim of this study, based on a large series of 101 HIV-1/Oinfected patients living in France, was to obtain unique and reliable data on the clinical features of this population and on the immunological and virological responses to combination ART (cART).
PATIENTS AND METHODS

The ORIVAO Study
The ORIVAO (Observatoire de la Réponse Immunovirologique aux Antirétroviraux chez les patients infectés par un VIH-1 du groupe O, vivant en France) study was performed between April 2012 and May 2014 in 48 French clinical centers. Inclusion criteria were all HIV-1/O-positive patients (irrespective of the year of diagnosis) followed in France. Data on routine clinical care, available in the clinical file, were collected and included plasma viral load (pVL), CD4 cell count, ART history, and clinical AIDS events.
The study was approved by the North-West III Ethics committee.
HIV-1/O Diagnosis and Monitoring
HIV-1/O diagnosis was established by env serotyping that is an enzyme-linked immunosorbent assay (ELISA) using synthetic peptides as antigens (Supplementary Methods), followed by molecular confirmation and phylogenetic characterization, using HIV-1/O-specific reverse-transcription polymerase chain reaction (RT-PCR) assays (Supplementary Methods) .
Plasma viral loads (pVLs) were monitored using non-groupspecific commercial kits (LCx or RealTime HIV-1, Abbott Molecular, Rungis, France; Cobas TaqMan HIV-1 version 2.0, Roche, Meylan, France) or HIV-1/O-specific quantitative RT-PCR developed by NRC, targeting either the long terminal repeat (LTR) or integrase regions (Supplementary Methods).
Statistical Analysis
Patient characteristics were described by continuous variables expressed as median and interquartile ranges (IQRs), and qualitative variables expressed as frequency and percentage. Immunological and virological characteristics at diagnosis were defined as the first CD4 cell count and pVL obtained within the first year after HIV diagnosis, and before any ART initiation.
Three different calendar periods taking into account evolution of ARV classes were considered: (1) The natural evolution of HIV-1/O infection was explored by monitoring progression to Centers for Disease Control and Prevention (CDC) clinical stage C and decrease in CD4 cell counts before treatment initiation. The time to reach clinical stage CDC C before ART, among patients diagnosed at stage A or B, was analyzed by using Kaplan-Meier survival curves. This method was used as only 2 patients were lost to follow-up Figure 1 . Flowchart of the selection of HIV-1/O-infected patients to study the response to combination antiretroviral therapy (cART) in the longitudinal approach from cART initiation (left) and the cross-sectional approach from 2007 (right). cART was defined as a treatment regimen with at least 3 antiretroviral drugs. Nonnaive patients at cART initiation were those who previously received mono-or dual antiretroviral therapy. and no death was observed before the occurrence of the outcome. Decreases in CD4 between diagnosis and treatment initiation (or before loss to follow-up) were modeled among patients with at least 1 CD4 value while still untreated. These decreases were studied using a piecewise linear mixed-effects model to account for the correlation between values in a given subject. CD4 decreases were modeled during the first 64 months following HIV diagnosis, as this corresponds to the third quartile of the distribution of times between HIV diagnosis and the last available CD4 measurement while still untreated.
Immunological and virological responses to cART (defined as a treatment regimen with at least 3 ARV drugs) were analyzed using 2 approaches: (1) a longitudinal approach, and (2) a cross-sectional approach (Figure 1 ).
In the longitudinal approach, responses to cART were analyzed in ARV-naive patients starting from cART initiation. CD4 counts and pVL values obtained between 2 months before and 7 days after cART initiation were considered as baseline values.
cART was considered to have ended if it was interrupted for >1 month, or in case of a switch to monotherapy or dual therapy. Immunological response to cART was analyzed for patients with at least 1 CD4 value. All values available from the initiation to the end of cART were considered. The gain of CD4 was modeled using a piecewise linear mixed-effects model, with 2 slopes and both fixed and random effects for the intercept and the slopes. The best model was chosen using Akaike information criteria. CD4 cell count kinetics were analyzed using a square root (√) scale to obtain a normal distribution for the description of the evolution of CD4 counts. Virological response was analyzed for patients with at least 1 pVL value within the first year of cART, aside from the initiation pVL. Kaplan-Meier survival curves were used to analyze the time to achieve a first pVL <200 copies/mL; this threshold was chosen to take into account the limit of quantification of some older assays (Supplementary Methods). The Clinical events: esophageal Candida infection (n = 2), Mycobacterium avium complex infection (n = 1), cytomegalovirus infection (n = 1), Pneumocystis carinii (n = 1), cytomegalovirus retinitis infection (n = 2), pulmonary bacilliform tuberculosis (n = 1), cerebral toxoplasmosis (n = 1), Salmonella septicemia (n = 1), cachexia syndrome due to HIV (n = 1).
analysis was repeated in the subset of patients monitored by a more recent assay with a threshold of 40 copies/mL. KaplanMeier survival methods were used since no mortality or lost to follow-up events occurred before the occurrence of the outcome.
Owing to the natural in vitro resistance of HIV-1/O to NNRTIs, we focused on responses to NNRTI-based regimens taken as first-line cART and compared them to the responses to first-line PI/r-based regimens. NNRTI-based and PI/r-based immunological responses were compared by introducing a variable "treatment" in the model, and testing interaction terms between treatments and slopes. For this analysis, patient follow-up data were censored at the end of first-line ARV treatment, that is, at the end of the NNRTI-or PI/r-based regimen. Virological response could not be compared between the 2 groups owing to the insufficient number of pVL measurements for patients initiating the NNRTI-based regimens.
In the cross-sectional approach, immunological and virological responses were determined for all patients still being followed during the most recent calendar period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , regardless of the previous ART regimens they received. Two groups were described to account for the impact of having received several regimens before 2007: patients with treatment initiated either (1) Analyses were performed using Stata software version 13 (StataCorp, College Station, Texas).
RESULTS
Clinical Features of the HIV-1/O Patients
Between April 2012 and May 2014, 101 patients identified in 48 clinical centers were enrolled in the study (Table 1 ; Supplementary Results).
The median CD4 count at HIV diagnosis was 250 cells/μL (Table 1) , and 40% patients had <200 cells/μL; the median pVL value at HIV diagnosis was 4.0 log 10 copies/mL. At diagnosis, 89.1% patients were stage A or B and 10.9% were stage C. Among the stage A or B patients, ART was initiated in 5 patients at diagnosis and in 82 patients within a median of 0.7 (IQR, 0.2-5.0) years after HIV diagnosis; 3 were lost to follow-up before initiating ART, with a median of 2.1 (IQR, 2.1-8.0) years following diagnosis. Among the 85 stage A or B patients without treatment initiation at diagnosis, 8 reached stage C before ART initiation and 1 before being lost to follow-up, due to the development of opportunistic infections. The cumulative probability of reaching stage C was 9.0% (95% confidence interval [CI], 3.7%-21.0%) and 16.6% (95% CI, 7.7%-33.7%), 1 and 5 years, respectively, after HIV diagnosis.
We analyzed the natural evolution of CD4 counts for the 66 patients who had at least 1 CD4 measurement while still untreated (median, 2 [IQR, [1] [2] [3] [4] ) measurements before treatment initiation, measured over a median period of 26.9 (IQR, months following diagnosis). The estimated average decrease of CD4 counts was -30.5 (95% CI, -40.3 to -18.7) cells/μL/year.
Immunological and Virological Responses to cART
We focused on the 80 naive patients with cART initiation (Table 1; Figure 1 ). cART was initiated after a median of 0.51 years after HIV diagnosis (Table 2) , and the median year of cART initiation was 2004 (IQR, 2002 (IQR, -2009 . At cART initiation, the median CD4 count was 201 cells/μL, with a median pVL 4.1 log 10 copies/mL ( Table 2 ). The regimens initiated were preferentially 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus 1 PI/r (51.3%), followed by 2 NRTIs plus 1 NNRTI (18.8%); initiation with an NNRTI-based regimen was related to later diagnosis of HIV-1/O status (Supplementary Results).
We analyzed the immunological response to cART of the 74 patients who had at least 1 available CD4 measurement since cART initiation (median, 12 [IQR, (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) pVL at initiation, log 10 copies/mL n=26
Median (IQR) 4.1 (3.6-4.6) cART regimen at initiation 2 NRTIs + 1 PI/r 51.3% (41) 2 NRTIs + 1 NNRTI 18.8% (15) 2 NRTIs + 1 PI 16.3% (13) 3 NRTIs 12.5% (10) 3 NRTIs + 1 PI/r + 1 PI 1.3% (1) Duration of cART, y n=79
Median (IQR) 4.1 (1.5-7.9) Data are presented as % (No.) unless otherwise indicated.
Abbreviations: cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted protease inhibitor; pVL, plasma viral load.
Owing to the natural in vitro resistance of HIV-1/O to NNRTIs, we specifically analyzed the immunological response of the 14 patients who received a first-line NNRTI-based regimen and compared their response to that of the 37 patients who received a first-line PI/r-based regimen. The modeled CD4 dynamics are shown in Figure 3 . The first increase tended to be smaller for patients on an NNRTI-based regimen than patients on a PI/r-based regimen, although the difference was of borderline significance (P = .09). After these first 4 months, the slope for the PI/r group continued to increase significantly (P < .001), whereas there was no further gain of CD4 within the NNRTI group (P = .56) ( Table 3 ). The model predicted that after 12 months of cART, a patient starting cART at 200 CD4 cells/μL would reach a mean of 377 (95% CI, 343-414) CD4 cells/μL for the PI/r-based regimen vs 279 (95% CI, 214-354) CD4 cells/μL for the NNRTI-based regimen (P = .02).
We analyzed the virological response for the 49 patients who had at least 1 pVL measurement available within the first year of cART, except at initiation. Forty-five (91.8%) patients reached a pVL <200 copies/mL; the median time taken to reach a pVL <200 copies/mL after cART initiation was 3.1 (IQR, 1.4-4.9) months. The cumulative probability of having a viral load <200 copies/mL after 6 and 12 months of cART was 0.81 (95% CI, .69-.91) and 0.85 (95% CI, .74-.94), respectively ( Figure 4 ). In the 28 monitored patients with a virological threshold of 40 copies/mL, 25 (89.3%) reached a pVL <40 copies/mL with a median of 3.8 (IQR, 2.0-5.5) months following cART initiation. The cumulative probability of having a pVL <40 copies/mL after 6 and 12 months of cART was 0.78 (95% CI, .65-.94) and 0.96 (95% CI, .81-.99), respectively. There was a trend toward a faster virological response in patients who started cART in 2007 or thereafter (Supplementary Results).
Current Management of HIV-1/O Patients
Between 2007 and 2014, 85 of the 101 (84%) enrolled patients were still on active follow-up and were all receiving cART. At the most recent follow-up visit, the median CD4 count was 498 (IQR, 381-612) cells/μL; 48% of the patients (41/85) had CD4 counts >500 cells/μL. Among the 77 patients with treatment initiation >6 months before, 87% had a pVL <40 copies/mL, which Figure 2 . Predicted evolution of √CD4 counts from the piecewise linear mixed-effects model (solid line) and √CD4 observed during combination antiretroviral therapy (cART; solid circles). N = 74 patients, with at least 1 CD4 cell count at initiation or during cART. CD4 counts were modeled on a square root scale, with 2 slopes, 0-4 months and after 4 months of cART. Abbreviation: rcd4, √CD4. rose to 90.5% among the 21 patients with an ongoing regimen that included an integrase strand transfer inhibitor (INSTI).
Among these 85 patients, cART was initiated in 57 before 2007: 37% with 2 NRTIs + 1 PI/r, 32% with 2 NRTIs + 1 PI, 18% with 2 NRTIs + 1 NNRTI, and 14% with 3 NRTIs. At cART initiation, they had a median CD4 count of 213 cells/μL and the median pVL was 4.3 log 10 copies/mL (Table 4) . Their most recent visit occurred after a median 12.8 (IQR, years of treatment, a period during which they received a median of 8 (IQR, (5) (6) (7) (8) (9) (10) (11) (12) different ART regimens. The most recently received treatment was a PI/r-or INSTI-based regimen (40.3% and 36.8%, respectively; Table 4 ). The most recent CD4 measurement was a median of 498 cells/μL; 85.2% of the patients had a pVL <40 copies/mL.
In 28 patients, cART was initiated in 2007 or thereafter: 78.6%, 17.9%, and 3.6% (n = 1) with a PI/r-based, an NNRTIbased, and a PI-based regimen, respectively. At treatment initiation, they had a median of 256 CD4 cells/μL and a pVL of 4.1 log copies/mL. At the most recent follow-up visit, 78.6% were receiving a PI/r-based and 14.3% an INSTI-based regimen.
The most recent CD4 count was a median of 506 cells/μL and among the 23 patients with cART initiation >6 months before, 91.3% had a pVL <40 copies/mL.
DISCUSSION
The HIV genetic diversity surveillance system, implemented at the end of the 1990s in France, resulted in the identification of many HIV-1/O cases outside the endemic area in Cameroon. This allowed us to follow the largest series of HIV-1/O patients to date, and thus to better characterize this particular population and evaluate its immunovirological response to cART.
We observed that 80% of the 101 patients originated from Cameroon or another sub-Saharan African country. This characteristic can be explained by strong and historical links between France and Cameroon, and suggests absence of a current secondary epidemic in France.
The only available data concerning the natural evolution of HIV-1/O infection resulted from 4 cases, which only described CD4 progression [18, 19, 21] . Here, we quantified the spontaneous decrease of CD4 and clinical progression. Among the 101 patients, 89% were diagnosed at stage A or B, with an estimated 16.6% (95% CI, 7.7%-33.7%) probability of becoming stage C 5 years after diagnosis. This estimate is close to that based on the natural history of the virus in HIV-1/M subjects [31, 32] , determined in populations with known seroconversion dates. However, a formal comparison is difficult, due to the low number of AIDS-defining events in our population and to unknown seroconversion dates. We also estimated that the rate of CD4 decrease before ART initiation was -30.5 cells/μL/year. This decrease was less pronounced than for HIV-1/M (from -49 to -63 cells/μL/year) [33] , but more than for HIV type 2 (HIV-2) (-11 cells/μL/year), a major variant known to be less pathogenic than HIV-1 [34] . Our data suggest that the spontaneous evolution of HIV-1/O infections may be between that of HIV-1/M and HIV-2. This could be linked to a median pVL of 4.0 log 10 copies/mL at HIV-1/O diagnosis, between 2.6 log 10 copies/mL for HIV-2 and 4.4 log 10 copies/mL for HIV-1/M patients [34] . This apparently lower value relative to HIV-1/M requires confirmation in clinical studies with comparable group O and group M populations, and exploration by complementary in vitro Data in parentheses are 95% confidence intervals.
Abbreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor. a P value of the comparison of the 2 groups.
b P value of the slope compared to zero. Figure 4 . Kaplan-Meier function time to achieve a first viral load value <200 copies/mL (n = 49) from combination antiretroviral therapy (cART) initiation in human immunodeficiency virus type 1 group O-infected patients. The number of patients still at risk at various time-points following cART initiation is depicted under the graph. Abbreviations: CI, confidence interval; cp, copies; HIV, human immunodeficiency virus; pVL, plasma viral load.
analyses focusing on group O fitness, as it was previously reported as lower than for group M and HIV-2 [35] . This work also provided the opportunity to evaluate immunological and virological responses to cART in the specific context of care standards in high-income countries. Previous cases have been reported, but with early-generation ART [26, 29, 30] or recent drugs in the context of salvage therapies [25, 27, 28] . Here, we show that cART initiation led to a large mean gain of 147 CD4 cells/μL after 1 year and an overall mean of 200 CD4 cells/μL. A virological response <40 copies/mL was achieved for almost 90% of patients, after a median of 3.8 months following cART initiation, and even earlier (3.1 months) in patients with cART initiation in 2007 or thereafter, that is, with the most recent cART regimens (Supplementary Results). Fifty percent of patients followed between 2007 and 2014 had >500 CD4 cells/μL and 87% had a pVL <40 copies/mL at their last visit (reaching >90% in the most recently treated patients). Our data are in accordance with current observations in the overall HIV population followed in France, with 56.7% of patients with >500 CD4 cells/μL and 88.5% with a pVL <50 copies/mL in the ANRS-VIH: Enquête sur les Personnes Atteintes (VESPA2) study [36] , and in patients born outside France in the French Hospital Database on HIV (FHDH) cohort, including 80% of patients from sub-Saharan Africa, with 47% with >500 CD4 cells/μL and 84% with a pVL <50 copies/mL [37] . These data demonstrate that current management of HIV-1/O infection based on to HIV-1/M guidelines is highly efficient despite genetic divergence.
However, we found an unexpectedly high frequency (18%) of cART initiation with an NNRTI regimen, although this therapeutic class is not recommended, due to natural resistance of HIV-1/O [22, 23] . This was clearly linked to the delayed knowledge of HIV-1/O status at cART initiation, as previously observed for HIV-2, the other major variant that is naturally resistant to NNRTIs [38] . Initiation with an NNRTI-based regimen resulted in a smaller gain of CD4 than initiation with a PI/r-based regimen 1 year after initiation, with a difference of around 100 CD4 cells/μL. This is likely related to virological failure, although the insufficient number of pVL measurements for these patients prevented us from demonstrating it. A similar evolution of CD4 increase was observed in HIV-2-infected patients receiving NNRTI(s), with a sharp halt in the CD4 increase after 2 months of treatment [38] . These results highlight the importance of identifying the variant before cART initiation.
In conclusion, this work allowed us to obtain unique and reliable data on HIV-1/O patients, their clinical features, and therapeutic management, in France. These results also underline that ad hoc studies between M and O populations with similar clinical and demographic characteristics are needed to definitively compare HIV-1/M and HIV-1/O natural and under cART courses. Finally, although most of our study population was from sub-Saharan Africa, our results are not necessarily representative of the situation for the population living in Cameroon, where medical care and treatment are different to those available in France. Furthermore, our Cameroonian population living in France may be a selected population due to the well-known "healthy migrant effect" [39] . Local observation is therefore needed to evaluate the current situation in the endemic area, in particular due to the frequent use of NNRTIbased first-line regimens, without systematic identification of HIV-1/O.
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